We have located links that may give you full text access.
Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.
Neuro-oncology 2020 January 31
BACKGROUND: The optimal radiation dose for adult supratentorial low grade glioma is unknown. The aim of this study was to provide a final update on oncologic and cognitive outcomes of high dose versus low dose radiation for low-grade glioma.
METHODS: Between 1986 and 1994, 203 patients with supratentorial low grade glioma were randomized (1:1) to 50.4 Gy in 28 fractions versus 64.8 Gy in 36 fractions after any degree of resection.
RESULTS: For all patients, median OS was 8.4 years (95% CI: 7.2 - 10.8). Median progression-free survival (PFS) was 5.2 years (95% CI: 4.3 - 6.6). Median follow-up is 17.2 years for the 33 patients still alive.
CONCLUSIONS: Long-term follow-up indicates no benefit to high-dose over low-dose radiation for low-grade gliomas. Cognitive function appeared to be stable after radiation as measured by MMSE.
METHODS: Between 1986 and 1994, 203 patients with supratentorial low grade glioma were randomized (1:1) to 50.4 Gy in 28 fractions versus 64.8 Gy in 36 fractions after any degree of resection.
RESULTS: For all patients, median OS was 8.4 years (95% CI: 7.2 - 10.8). Median progression-free survival (PFS) was 5.2 years (95% CI: 4.3 - 6.6). Median follow-up is 17.2 years for the 33 patients still alive.
CONCLUSIONS: Long-term follow-up indicates no benefit to high-dose over low-dose radiation for low-grade gliomas. Cognitive function appeared to be stable after radiation as measured by MMSE.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app